Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity

Endocrine. 2000 Oct;13(2):193-9. doi: 10.1385/ENDO:13:2:193.

Abstract

Drugs that act through noradrenergic and serotonergic mechanisms have historically served as the mainstays of pharmacologic treatments for obesity. This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets.

Publication types

  • Review

MeSH terms

  • Adrenergic Agents / therapeutic use*
  • Appetite Depressants / adverse effects
  • Appetite Depressants / therapeutic use*
  • Cyclobutanes / adverse effects
  • Cyclobutanes / therapeutic use*
  • Dexfenfluramine / adverse effects
  • Dextroamphetamine
  • Fenfluramine / adverse effects
  • Heart Valve Diseases / chemically induced
  • Humans
  • Obesity / drug therapy*
  • Phenylpropanolamine
  • Serotonin Agents / therapeutic use*
  • Weight Loss

Substances

  • Adrenergic Agents
  • Appetite Depressants
  • Cyclobutanes
  • Serotonin Agents
  • Fenfluramine
  • Phenylpropanolamine
  • Dexfenfluramine
  • Dextroamphetamine
  • sibutramine